Immunovant, Inc. (IMVT) Cash Flow Statement
Immunovant, Inc. (IMVT) generated -$414.3M of operating cash flow over the twelve months to 2026-06-30, spent -$7.0M on capital expenditure and had free cash flow of -$407.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IMVTImmunovant, Inc.Follow IMVT — free
—
Price chart with a free account
- Market cap
- 5.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2020 Mar 20 | FY2021 Mar 21 | FY2022 Mar 22 | FY2023 Mar 23 | FY2024 Mar 24 | FY2025 Mar 25 | FY2026 Mar 26 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -53.4 | -83.3 | -106.1 | -188.2 | -214.2 | -375.9 | -407.3 | -414.3 | |
| Capital expenditure | 0.0 | 0.2 | 0.3 | 0.2 | 0.4 | 0.8 | 0.0 | 7.0 | |
| Free cash flow | -53.4 | -83.5 | -106.4 | -188.4 | -214.6 | -376.6 | -407.3 | -407.3 | |
| Stock-based compensation | 7.0 | 18.8 | 34.2 | 32.3 | 41.1 | 49.5 | 55.7 | — |
USD millions · SEC XBRL
Immunovant, Inc. — questions
- What is Immunovant, Inc.'s operating cash flow?
- -$414.3M over the twelve months to 2026-06-30.
- How much does Immunovant, Inc. spend on capital expenditure?
- -$7.0M over the twelve months to 2026-06-30.
- What is Immunovant, Inc.'s free cash flow?
- -$407.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Immunovant, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.